Stefano Pallanti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/396512/publications.pdf

Version: 2024-02-01

52 papers

2,424 citations

304602 22 h-index 214721 47 g-index

53 all docs 53 docs citations

53 times ranked

2684 citing authors

#	Article	IF	CITATIONS
1	Treatment non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology, 2002, 5, 181-91.	1.0	325
2	Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 400-412.	2.5	292
3	Reliability and Validity of the Pathological Gambling Adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). Journal of Gambling Studies, 2005, 21, 431-443.	1.1	200
4	Lithium and Valproate Treatment of Pathological Gambling. Journal of Clinical Psychiatry, 2002, 63, 559-564.	1.1	122
5	Think twice: Impulsivity and decision making in obsessive–compulsive disorder. Journal of Behavioral Addictions, 2015, 4, 263-272.	1.9	107
6	Comorbidity in obsessiveâ€"compulsive disorder (OCD): A report from the International College of Obsessiveâ€"Compulsive Spectrum Disorders (ICOCS). Comprehensive Psychiatry, 2014, 55, 1513-1519.	1.5	105
7	Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2011, 72, 716-721.	1.1	101
8	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology, 2019, 29, 971-985.	0.3	93
9	Early intervention for obsessive compulsive disorder: An expert consensus statement. European Neuropsychopharmacology, 2019, 29, 549-565.	0.3	92
10	Obsessive–Compulsive Disorder Comorbidity: Clinical Assessment and Therapeutic Implications. Frontiers in Psychiatry, 2011, 2, 70.	1.3	90
11	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	4.1	68
12	Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder. CNS Drugs, 2009, 23, 1047-1055.	2.7	54
13	Childhood, adolescent and adult age at onset and related clinical correlates in obsessive–compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). International Journal of Psychiatry in Clinical Practice, 2016, 20, 210-217.	1.2	50
14	Nefazodone Treatment of Pathological Gambling. Journal of Clinical Psychiatry, 2002, 63, 1034-1039.	1.1	50
15	An expert opinion on PANDAS/PANS: highlights and controversies. International Journal of Psychiatry in Clinical Practice, 2017, 21, 91-98.	1.2	43
16	Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology. Comprehensive Psychiatry, 2020, 100, 152184.	1.5	38
17	Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation. European Neuropsychopharmacology, 2014, 24, 375-380.	0.3	37
18	Anxiety as a Core Aspect of Schizophrenia. Current Psychiatry Reports, 2013, 15, 354.	2.1	32

#	Article	IF	CITATIONS
19	Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive–compulsive disorder, mini-review and pilot open-label trial. Journal of Psychopharmacology, 2016, 30, 568-578.	2.0	30
20	Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. International Journal of Psychiatry in Clinical Practice, 2017, 21, 156-159.	1.2	30
21	Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2018, 23, 59-66.	0.7	30
22	Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. International Journal of Psychiatry in Clinical Practice, 2021, 25, 115-131.	1.2	27
23	Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. International Clinical Psychopharmacology. 2021. 36. 61-75.	0.9	27
24	Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. Journal of Psychiatric Research, 2020, 130, 215-217.	1.5	25
25	Basal Ganglia Activity in Pathological Gambling: A Fluorodeoxyglucose-Positron Emission Tomography Study. Neuropsychobiology, 2010, 62, 132-138.	0.9	23
26	Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults. Expert Opinion on Pharmacotherapy, 2018, 19, 1541-1550.	0.9	23
27	Emerging drugs to treat obsessive–compulsive disorder. Expert Opinion on Emerging Drugs, 2014, 19, 67-77.	1.0	20
28	From Treatment Response to Recovery: A Realistic Goal in OCD. International Journal of Neuropsychopharmacology, 2018, 21, 1007-1013.	1.0	20
29	Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation. Frontiers in Behavioral Neuroscience, 2019, 13, 70.	1.0	19
30	Addicted to compulsion: assessing three core dimensions of addiction across obsessive-compulsive disorder and gambling disorder. CNS Spectrums, 2020, 25, 392-401.	0.7	19
31	Resistant social anxiety disorder response to Escitalopram. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 35.	0.6	18
32	Obsessive-Compulsive Disorder Spectrum as a Scientific "Metaphor― CNS Spectrums, 2008, 13, 6-15.	0.7	18
33	rTMS in resistant mixed states: An exploratory study. Journal of Affective Disorders, 2014, 157, 66-71.	2.0	18
34	Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2015, 20, 469-473.	0.7	18
35	Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and their Treatment Implications. Current Neuropharmacology, 2019, 17, 672-680.	1.4	18
36	<i>Bacopa monnieri</i> as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. Phytotherapy Research, 2020, 34, 2331-2340.	2.8	17

3

#	Article	IF	CITATIONS
37	Antibiotics for PANDAS? Limited Evidence. primary care companion for CNS disorders, The, 2018, 20, .	0.2	14
38	A transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: An international Delphi consensus study. Australian and New Zealand Journal of Psychiatry, 2020, 54, 719-731.	1.3	13
39	A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry, 2004, 65 Suppl 14, 6-10.	1.1	13
40	Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation. Journal of Neurology, 2010, 257, 1362-1368.	1.8	12
41	Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2020, 25, 419-425.	0.7	10
42	Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: results of a multicenter Italian study. CNS Spectrums, 2021, 26, 354-361.	0.7	10
43	The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. Comprehensive Psychiatry, 2022, 116, 152315.	1.5	9
44	Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology. Journal of Psychiatric Research, 2021, 140, 357-363.	1.5	7
45	Cariprazine in the management of negative symptoms of schizophrenia: stateÂofÂtheÂart and future perspectives. Future Neurology, 2020, 15, .	0.9	7
46	Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder. Journal of Psychiatric Research, 2022, 149, 367-373.	1.5	7
47	Transcranial Magnetic Stimulation for the Treatment of Pharmacoresistant Nondelusional Auditory Verbal Hallucinations in Dementia. Case Reports in Psychiatry, 2013, 2013, 1-6.	0.2	6
48	"A Theta Burst Stimulation on Pre-SMA: Proof-of-Concept of Transcranial Magnetic Stimulation in Gambling Disorder― Journal of Gambling Studies, 2022, 38, 1529-1537.	1.1	4
49	Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. Clinical Practice and Epidemiology in Mental Health, 2005, $1,24$.	0.6	3
50	Brain Plasticity and Brain Stimulation in Neuropsychiatry: Toward Individualized Medicine. CNS Spectrums, 2008, 13, 287-292.	0.7	3
51	Problematic Internet use: is it more compulsory than rewarding or mood driven?. World Psychiatry, 2010, 9, 96-97.	4.8	3
52	Outcomes with Neuromodulation in Obsessive-Compulsive Disorder. Psychiatric Annals, 2015, 45, 316-320.	0.1	3